China's medical products administrator granted Hutchmed (HKG:0013) breakthrough therapy designation for its combination of savolitinib and osimertinib for a mutation of non-small cell lung cancer, according to a Thursday filing with the Hong Kong Exchange.
The drug combination is undergoing phase 3 trials in China, the filing said.
The breakthrough designation is given to drugs that treat life-threatening illnesses with no known treatment options and with clinical evidence showing advantages over other existing therapies, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。